Lisieux

Mood disorders such as depression and bipolar disorder affect many people worldwide and lead to serious psychological, cognitive, and social difficulties. These conditions place a heavy burden on healthcare systems. The trial evaluates Edra PRO, a digital medical device designed to support clinical decisions and remotely monitor symptoms in psychiatric patients. The study compares Edra PRO with usual care to assess effects on symptoms, quality of life, healthcare costs, comorbidities, and user satisfaction and adherence. Participants will be randomly assigned to either use Edra PRO, which offers remote monitoring through software, or receive standard care without this device. The study is designed as a randomized controlled trial with a single masking approach. The main study period lasts six months, during which the effects of the device on depression symptoms and other outcomes will be assessed. During the trial, participants will be monitored for response to treatment over six months. Researchers will also evaluate the safety and reliability of Edra PRO, its impact on quality of life, and economic effects compared to usual care. Participants must have access to a smartphone and internet and be able to use the device independently. The study aims to gather data on symptom changes, healthcare use, user satisfaction, and adherence over the study period.

Researchers are collecting biological samples to improve diagnosis and treatment of rare neuroimmune disorders affecting the central and peripheral nervous system. These disorders include Paraneoplastic Neurological Syndromes PNS and Autoimmune Encephalitis AE, which involve immune system activity. The study aims to support faster and more accurate diagnosis, benefiting patients with these conditions by enhancing future treatment approaches. Participants diagnosed with PNS or AE will have biological samples collected once, including blood and possibly cerebrospinal fluid if available. Blood samples will be used to obtain serum, buffy coat, plasma, and peripheral blood mononuclear cells. If cerebrospinal fluid is drawn for diagnosis, any remaining sample will be stored. This collection will occur during a single visit, and samples will be stored for up to 10 years. During the study, participants will provide consent and undergo sample collection only once. Researchers will monitor the blood samples and cerebrospinal fluid biocollection over 10 years. The study emphasizes scientific collaboration and ongoing research to improve understanding and treatment of these neurological disorders. Participation duration focuses on the collection and long-term storage of biological samples.